U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241338) titled 'Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity' on Nov. 13.
Brief Summary: To compare the efficacy and safety of sacubitril/Allisartan versus amlodipine in the antihypertensive treatment of overweight/obese patients with primary hypertension
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Hypertension
Intervention:
DRUG: sacubitril/allisartan
Oral administration of sacubitril/allisartan 240mg once daily for 4 consecutive weeks. If blood pressure reaches the target, the original regimen is continued; otherwise, the dose of sacubitril/valsartan is increased to 480mg once daily for ...